



American Academy of
Orthopaedic Surgeons®

AAOS

American Association of
Orthopaedic Surgeons

6300 North River Road Rosemont, IL 60018-4262
Phone 847/823-7186, 800/346-2267 Fax 847/823-8125 Fax-on-Demand 800/999-2939 Internet www.aaos.org

0300 '99 DEC 28 1993

December 21, 1999

Jane E. Henney, MD
Commissioner
Food and Drug Administration (FDA)
5630 Fishers Lane, Room 1061
Rockville, Maryland 20852

Dear Dr. Henney:

The American Academy of Orthopaedic Surgeons (AAOS), representing over 16,000 Board certified orthopaedic surgeons, is pleased to take this opportunity to comment on the Proposed Rule: Suitability Determination for Donors of Human Cellular and Tissue-Based Products. (Published in the Federal Register on Thursday, September 30, 1999). (Docket No. 97N-484S).

Inasmuch as the proposed rule enhances protections for the public regarding tissue transplantation, the AAOS fellowship is supportive of its overall requirements. As described in the proposed rule, essentially all of the tissue banks currently involved in processing and distribution of musculoskeletal related tissues of concern to the AAOS are already in compliance with the proposed requirements.

However, the AAOS would like to raise a few issues of concern with regard to FDA's regulation of human and cellular based tissue products.

First, we are unsure how the definition of "minimally manipulated tissue" may affect the FDA decisions in the regulation of particular tissue products. As it is currently written, this definition is confined to an extremely brief paragraph within the proposed rule. While the Center for Biologics, Evaluation and Research (CBER) 1997 guidance document "Proposed Approach to Regulation of Cellular and Tissue-Based Products" may provide some clarification as to what the FDA may define as "minimally manipulated tissue," the evolution of new methods, processing approaches, materials, and combinations of tissues, materials and cells, may create significant confusion or ambiguities as to what products do or do not fall within the FDA regulatory scope.

Future advancements in technologies and in the processing of human cellular and tissue-based products may put most tissue outside of the narrow definition of the proposed rule when in fact, a broader definition of "minimally

manipulated tissue," may be more appropriate. The Academy suggests that substantially more detailed guidance regarding this definition needs to be developed prior to the implementation of the rule.


Of additional concern, is that there is no requirement for osteoinductive bone graft substitutes derived from human tissues by minimally manipulative procedures to be tested for osteoinductive capacity by bioassay. The American Society for Testing and Materials (ASTM) has recently developed a draft standard for the testing of osteoinduction. Inclusion of an accepted standard may enhance public protection by providing improved quality control.

Finally, it is not clear why family-related allogeneic tissue donation is exempted from donor suitability requirements, particularly in light of potential social factors which may impair thorough disclosure of possible health-related risk factors in donor screening.

We share the concerns of the FDA in ensuring that safe and effective products enter the marketplace. We remain committed to ensuring the availability of safe tissues and tissue-based products to enhance the treatment of disease and injury and remain committed to protecting consumers and our patients.

Thank you for your efforts. We welcome the opportunity to work with you on these matters.

Sincerely,


William W. Tipton, Jr., MD
Executive Vice President

FedEx USA AirbillFedEx
Tracking
Number

805841228714

Form
I.D. No.

0210

Recipien's Copy

1 From Date 1/23/99
Sender's Name JEANIE KENNEDY Phone (847) 823-7186

Company AMER ACADEMY ORTHO SURGEONS
Address 6300 N RIVER RD Dept/Floor/Suite/Room

City ROSEMONT State IL ZIP 60018

2 Your Internal Billing Reference Information 7882-5670

3 To Recipient's Name DOCKEL MANAGEMENT BRANCH Phone (301) 827-6210

Company FDA (Food & Drug Administration)

Address 5630 FILLERS LANE, Rm. 1061 Dept/Floor/Suite/Room

City Rockville State MD ZIP 20852

For HOLD at FedEx Location check here☐ **Hold Weekday**
(Not available with
FedEx First Overnight)☐ **Hold Saturday**
(Not available at all locations)
(Available for FedEx Priority Overnight
and FedEx 2Day only)**For WEEKEND Delivery check here**☐ **Saturday Delivery**
(Available for FedEx Priority
Overnight and FedEx 2Day only)☐ **NEW Sunday Delivery**
(Available for FedEx
Priority Overnight only)☐ Check here
if residence
(Extra charge applies
for FedEx Express Saver)

805841228714

4a Express Package Service Packages under 150 lbs.

☐ FedEx Priority Overnight
(Next business morning)
☐ FedEx First Overnight
(Earliest next business morning delivery to select locations) (Higher rates apply)
☐ FedEx 2Day
(Second business day)
☐ FedEx Express Saver
(Third business day)
FedEx Letter Rate not available. Minimum charge: One pound rate.

Delivery commitment may
be later in some areas.**4b Express Freight Service Packages over 150 lbs.**

☐ FedEx Overnight Freight
(Next business day)
☐ FedEx 2Day Freight
(Second business day)
☐ FedEx Express Saver Freight
(Up to 3 business days)

Delivery commitment may
be later in some areas.

(Call for delivery schedule. See back for detailed descriptions of freight services.)

5 Packaging ☒ FedEx Letter ☐ FedEx Pak ☐ FedEx Box ☐ FedEx Tube ☐ Other Pkg.
Declared value limit \$500

6 Special Handling

Does this shipment contain dangerous goods? ☒ No ☐ Yes (No per attached Shipper's Declaration) (Shipper's Declaration not required)
☐ Dry Ice ☐ Cargo Aircraft Only
Dry Ice, 9, UN 1845, _____ kg. *Dangerous Goods cannot be shipped in FedEx packaging.

7 Payment

Bill to: ☒ Sender (Account No. in Section 1 will be billed) ☐ Recipient ☐ Third Party ☐ Credit Card ☐ Cash/Check
(Enter FedEx Account No. or Credit Card No. below)



Total Packages	Total Weight	Total Declared Value*	Total Charges
		\$.00	

*When declaring a value higher than \$100 per shipment, you pay an additional charge. See SERVICE CONDITIONS, DECLARED VALUE, AND LIMIT OF LIABILITY section for further information.

8 Release Signature

Your signature authorizes Federal Express to deliver this shipment without obtaining a signature and agrees to indemnify and hold harmless Federal Express from any resulting claims.

Questions?
Call 1-800-Go-FedEx® (800)463-3339

005553068 2

Rev. Date 12/97
Part #153023
©1994-97 FedEx
PRINTED IN U.S.A.
GDFE 4/98